摘要：Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016[J/OL]. New England Journal of Medicine, 2018: 2429

审批编号：MPR-CN-101998

有效期至2026年8月28日

参考文献：

1. 王陇德, 等. 《中国脑卒中防治报告 2020》概要[J]. 中国脑血管病杂志, 2022, 19(2): 136-144.

2. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016[J/OL]. New England Journal of Medicine, 2018: 2429-2437. http://dx.doi.org/10.1056/nejmoa1804492. DOI:10.1056/nejmoa1804492.

3. Menon B K, Buck B H, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial[J]. Lancet, 2022,400(10347):161-169.

4. Muir K W, Ford G A, Ford I, et al. Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial[J]. Lancet Neurol, 2024,23(11):1087-1096.

5. Parsons M W, Yogendrakumar V, Churilov L, et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial[J]. Lancet Neurol, 2024,23(8):775-786.

6. Yongjun Wang.Tenecteplase Versus Alteplase in Chinese Patients with Acute Ischaemic Stroke(ORIGINAL):A Multicenter Randomised Phase III Study[C].2024 European Stroke Organisation Conference（ESOC）;Presentation ID O118,May 16,2024,Basel,Switzerland.

声明：本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

来源：医脉通神经科